Veracyte to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 30, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie Anderson, president and chief executive officer, will present at the Cantor Fitzgerald 2^nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 11:15 a.m. ET in New York City.

The live audio webcast of the Veracyte corporate presentation from the Cantor Fitzgerald conference and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The webcast will be available shortly after its conclusion and archived on the company's website for 90 days following the presentation.

In addition to her corporate presentation and Q&A, Ms. Anderson will participate in a panel discussion on changes in the reimbursement environment and challenges molecular diagnostics labs encounter in achieving reimbursement, moderated by Cantor Fitzgerald's Life Science Tools & Diagnostics Analyst Bryan Brokmeier.

About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma® Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for 180 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta® Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. In the fourth quarter of 2016, Veracyte plans to launch its second pulmonology product, the Envisia™ classifier, to improve diagnosis of interstitial lung diseases including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

SOURCE Veracyte

Related Links

https://www.veracyte.com